Biomarkers of Human Pluripotent Stem Cell-Derived Cardiac Lineages
Rhys J P Skelton1, Timothy J Kamp2, David A Elliott3
1Division of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, CA 90095, USA.
Insights
Human pluripotent stem cells (hPSCs) are a valuable source for generating cardiac tissues. Identifying specific biomarkers helps isolate pure cardiac cell types for improved therapies and disease modeling.
Area of Science:
- Cardiovascular Biology
- Stem Cell Biology
- Developmental Biology
Background:
- Human pluripotent stem cells (hPSCs) are a promising source for generating cardiovascular lineages in vitro.
- Current differentiation protocols often result in mixed cell populations, including undesired cell types.
- Accurate identification of cardiac subpopulations is crucial for therapeutic and research applications.
Purpose of the Study:
- To review the current landscape of stage-specific biomarkers for cardiac lineage commitment from hPSCs.
- To provide a comprehensive resource for identifying and isolating pure cardiac subpopulations.
- To facilitate advancements in cardiac cell therapy, drug screening, and disease modeling.
Main Methods:
- Comprehensive literature review of published studies on hPSC differentiation and cardiac lineage markers.
- Analysis and categorization of identified biomarkers based on cardiac cell type and differentiation stage.
- Synthesis of information on the utility of these biomarkers for cell isolation and characterization.
Main Results:
- Numerous stage-specific biomarkers have been characterized for cardiomyocytes, smooth muscle cells, and endothelial cells derived from hPSCs.
- These biomarkers enable the isolation of major cardiac lineages and specific subpopulations from heterogeneous hPSC-derived cell mixtures.
- The identified markers provide a foundation for understanding the hierarchy of cardiac differentiation.
Conclusions:
- The development and application of specific biomarkers are critical for refining hPSC-based cardiac differentiation protocols.
- Pure cardiac cell populations isolated using these markers will advance cellular therapies, disease modeling, and drug discovery.
- This review consolidates knowledge on cardiac lineage biomarkers, supporting future research in cardiovascular regenerative medicine.
Abstract:
Human pluripotent stem cells (hPSCs) offer a practical source for the de novo generation of cardiac tissues and a unique opportunity to investigate cardiovascular lineage commitment. Numerous strategies have focused on the in vitro production of cardiomyocytes, smooth muscle, and endothelium from hPSCs. However, these differentiation protocols often yield undesired cell types. Thus, establishing a set of stage-specific markers for pure cardiac subpopulations will assist in defining the hierarchy of cardiac differentiation, aid in the development of cellular therapy, and facilitate drug screening and disease modeling. The recent characterization of many such markers is enabling the isolation of major cardiac lineages and subpopulations from differentiating hPSCs. We provide here a comprehensive review detailing the suite of biomarkers used to differentiate cardiac lineages from mixed hPSC-derived populations.
